Journal: Drug discoveries & therapeutics

Article Title: Construction of recombinant adenoviral vector carrying cyclinA2 gene.

doi: 10.5582/ddt.2014.01048

Figure Lengend Snippet: Figure 1. PCR identification of cyclinA2 gene. Lane 1: PCR products of cyclinA2 gene. Lane 2: negative control. M1: DL200 Maker (2,000, 1,000, 750, 500, 250, 100 bp). M2: DL15000 Maker (15,000, 10,000, 7,500, 5,000, 2,500, 1,000 bp).

Article Snippet: Human cyclinA2 cDNA clonewas purchased from OriGene Technologies (MD, USA).

Techniques: Negative Control

Journal: Drug discoveries & therapeutics

Article Title: Construction of recombinant adenoviral vector carrying cyclinA2 gene.

doi: 10.5582/ddt.2014.01048

Figure Lengend Snippet: Figure 2. Digestion of pDC316-CyclinA2-CMV-EGFP with NotI and EcoRV. M1: DL15,000 (15,000, 10,000, 7,500, 5,000, 2,500, 1,000 bp). M2: DL2000 (2,000, 1,000, 750, 500, 250, 100 bp). Lane 1: pDC316- CyclinA2-CMV-EGFP.

Article Snippet: Human cyclinA2 cDNA clonewas purchased from OriGene Technologies (MD, USA).

Techniques:

Journal: Drug discoveries & therapeutics

Article Title: Construction of recombinant adenoviral vector carrying cyclinA2 gene.

doi: 10.5582/ddt.2014.01048

Figure Lengend Snippet: Figure 4. RT-PCR identification of the recombinant adenovirus. Lane 1: Ad.CyclinA2-EGFP stock solution. Lane 2: Ad.CyclinA2-EGFP stock solution diluted 10 times. Lane 3: Ad.CyclinA2-EGFP stock solution diluted 100 times. Lane 4: Positive control (pDC316-CyclinA2-mCMV-EGFP). Lane 5: Negative control. M: DL2000 Marker (2,000, 1,000, 750, 500, 250, 100 bp).

Article Snippet: Human cyclinA2 cDNA clonewas purchased from OriGene Technologies (MD, USA).

Techniques: Reverse Transcription Polymerase Chain Reaction, Recombinant, Positive Control, Negative Control, Marker

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: Super enhancer-driven LINC01013 mediates hypoxia-induced mitochondrial dysfunction by HSPA9 to determine pulmonary arterial smooth muscle cell fate

doi: 10.1007/s00018-025-06071-3

Figure Lengend Snippet: Silencing of LINC01013 inhibited hypoxia-induced hPASMC proliferation and inflammation. A , B hPASMC proliferation was determined by CCK8 and EdU incorporation assays ( n = 6). EdU (red), DAPI (blue), scale bar, 50 μm. C Western blotting analysis of PCNA, cyclin A and cyclin D in hPASMCs ( n = 6). D RT‒qPCR analysis showed the mRNA levels of TNF-α and IL-6 after LINC01013 knockdown, β-actin was used as a internal reference gene ( n = 6). E Western blotting analysis of TNF-α and IL-6 in hPASMCs. ( n = 6). All values are presented as the mean ± SEM. Statistical analysis was performed with one-way ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001. Nor, normoxia; Hyp, hypoxia; NC, negative control; si, siRNA

Article Snippet: The antibody against CEBPB (PB9171, BA0670, 1:500, Boster, Wuhan, China), H3K27ac (A7253, 1:500, ABclonal, Wuhan, China), H3K4me1 (A2355, 1:500, Wuhan, China), PCNA (A00125, 1:500, Boster, Wuhan, China), Cyclin A (PB0515, 1:500, Boster, Wuhan, China), Cyclin D (BM4272, 1:500, Boster, Wuhan, China), IL-6 (AF7236, 1:500, Beyotime, Shanghai, China), TNF-α (AF8208, 1:500, Beyotime, Shanghai, China), PKM2 (4053, 1:1000, Cell Signaling, MA, US), HK II (66974-1-Ig, 1:1000, Proteintech, IL, USA), PDH (2784, 1:1000, Cell Signaling, MA, US), HSPA9 (14887-1-AP, 1:5000, Proteintech, IL, USA), VDAC1 (10866-1-AP, 1:5000, Proteintech, IL, USA), and β-actin (TA-09, 1:1000, ZSGB‐BIO, Beijing, China) was incubated at 4 °C overnight, followed by incubation with appropriate horseradish peroxidase-conjugated secondary antibodies at room temperature for 1 h, and proteins were visualized with enhanced chemiluminescence reagents.

Techniques: Western Blot, Knockdown, Negative Control